Beyond highlighting that clonal expansion and effector differentiation of stem-like TCF1+CD8+ T cells occurs within tumour tissue, as recently suggested1–3, our results reveal that this critical phase of protective anticancer immunity is selectively targeted by tumour-derived PGE2. Here, CD8A is linked to neoplasm.